European Journal of Vascular & Endovascular Surgery
Volume 25, Issue 1 , Pages 16-22 , January 2003

Increased platelet aggregation and activation in peripheral arterial disease

,Accepted 4 October 2002.

References 

  1. Furman M, Benoit S, Barnard M, et al.  Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol. 1998;31:352–358
  2. Ault K, Cannon C, Mitchell J, et al.  Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial: thrombolysis in myocardial infarction. J Am Coll Cardiol. 1999;33:634–639
  3. Grau A, Ruf A, Vogt A, et al.  Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischaemia. Thromb Haem. 1998;80:298–301
  4. Zeller J, Tschoepe D, Kessler C. Circulating platelets show increased activation in patients with acute cerebral ischaemia. Thromb Haem. 1999;81:373–377
  5. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn P. Blood platelet count and fuction are related to total and cardiovascular death in apparently healthy men. Circulation. 1991;84:613–617
  6. Trip M, Cats V, van Capelle F, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 1990;31:1549–1554
  7. Barradas M, Stansby G, Mikhailidis D. Diminished platelet yield and enhanced platelet aggregability in platelet rich plasma of peripheral vascular disease patients. Int Angiol. 1994;13:202–207
  8. Walters T, Mitchell D, Woods R. Low dose aspirin fails to inhibit increased platelet reactivity in patients with peripheral vascular disease. Br J Surg. 1993;80:1266–1268
  9. Dormandy J, Heeck L, Vig S. Lower extremity arteriosclerosis as a reflection of a systemic process: Implications for concommitant coronary and carotid disease. Sem Vasc Surg. 1999;12:118–122
  10. Leng G, Lee A, Fowkes F, et al.  Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral artery disease in the general population. Int J Epidemiol. 1996;25:1172–1181
  11. Criqui M, Denenberg J, Langer R, Fronek A. The epidemiology of peripheral arterial disease: the importance of identifying the population at risk. Vasc Med. 1997;2:221–226
  12. Leng G, Fowkes F, Lee A, Dunbar J, Housley E, Ruckley C. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ. 1996;313:1440–1444
  13. CAPRIE Steering Committee . A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1338
  14. Mikhailidis D, Jagroop I. Is clopidogrel markedly superior to aspirin in patients with peripheral vascular disease?. Platelets. 1998;9:273–278
  15. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J. 2002;324:71–86
  16. Robless P, Mikhailidis D, Stansby G. A systematic review of antiplatelet therapy for prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg. 2001;88:787–800
  17. Barnett H, Kaste M, Meldrum B, Eliasziw M. Aspirin dose in stroke prevention: Beautiful hypothesis slain by ugly facts. Stroke. 1996;27:588–592
  18. Barradas M, Stansby G, Mikhailidis D. Naftidrofuryl and Aspirin on platelet aggregation in peripheral vascular disease. In vivo. 1993;7:543–548
  19. Reininger C, Greinacher A, Graf J, Lasser R, Steckmeier B, Schweiberer L. Platelets of patients with peripheral arterial disease are hypersensitive to heparin. Thromb Res. 1996;81:641–649
  20. Smout J, Stansby G. Aspirin resistance. Br J Surg. 2002;89:4–5
  21. George J, Shattil S. The clinical importance of acquired abnormalities of platelet function. N Engl J Med. 1991;324:27–39
  22. Schmitz G, Rothe G, Ruf A, et al.  European working group on cell cycle analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost. 1998;79:885–896
  23. Shattil S, Cunningham M, Hoxie J. Detection of activated platelets in whole blood using activation dependant monoclonal antibodies and whole blood flow cytometry. Blood. 1987;70:307–315
  24. Robless P, Tegos T, Okonko D, et al.  Platelet activation during carotid endarterectomy and the antiplatelet effect of Dextran 40. Platelets. 2002;13:231–239
  25. Michelson A, Barnard M, Hechtman H, et al.  In vivo tracking of platelets: circulating degranulating platelets rapidly lose surface P-selectin but continue to circulate and function. Proceedings of the National Academy of Sciences of the United States of America. 1996;11877–11882
  26. Tschoepe D, Schultheib M, Kolarov P, et al.  Platelet membrane activation markers are predictive for acute ischaemic events after PTCA. Circulation. 1993;88:37–42
  27. Ishiwata S, Tukada T, Toshiyasu T, Nakanishi S, Nishiyama S, Seki A. Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J. 1997;133:387–392
  28. Ikeda H, Takajo Y, Ichiki K, et al.  Increased soluble form of P-selectin in patients with unstable angina. Circulation. 1995;92:1693–1696
  29. Kaikita K, Ogawa H, Yasue H, et al.  Soluble P-selectin is released into the coronary circulation after coronary spasm. Circulation. 1995;92:1726–1730
  30. Blann A, Dabrotova M, Kubisz P, McCollum C. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost. 1995;74:626–630
  31. Galt S, McDaniel M, Ault K, Mitchell J, Cronenwett J. Flow cytometric assessment of platelet function in patients with peripheral arterial occlusive disease. J Vasc Surg. 1991;16:747–756
  32. Michelson A. Flow cytometry: a clinical test of platelet function. Blood. 1996;87:4925–4936
  33. Valles J, Santos M, Aznar J, et al.  Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality. Circulation. 1998;97:350–355
  34. Ruggeri Z. Mechanisms initiating platelet thrombus formation. Thromb Haemost. 1997;78:611–616
  35. Barradas M, Mikhailidis D. Serotonin, histamine and platelets in vascular disease with specific reference to peripheral vascular disease. Braz J Med Biol Res. 1992;25:1063–1076
  36. Davi G, Gresele P, Violi F, et al.  Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo: evidence derived from the study of peripheral arterial disease. Circulation. 1997;96:69–75
  37. Schultheiβ H, Tschoepe D, Esser J, et al.  Large platelets continue to circulate in an activated state after myocardial infarction. Eur J Clin Invest. 1994;24:243–247
  38. Tschoepe D, Roesen P, Esser J, et al.  Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Haemost. 1991;13:857–862
  39. Wolf R, Peng J, Friese P, Gilmore L, Burstein S, Dale G. Erythropoietin administration increases production and reactivity of platelets in dogs. Thromb Haemost. 1997;78:1505–1509
  40. Awtry E, Loscalzo J. Aspirin. Circulation. 2000;101:1206–1218
  41. Samama C, Bonnin P, Boneau M, et al.  Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig. Thromb Haemost. 1992;68:500–505
  42. Herbert J, Tissinier A, Defreyn G, Maffrand J. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb. 1993;13:1171–1179
  43. Leon M, Baim D, Popma J, et al.  A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. N Engl J Med. 1998;339:1665–1671
  44. Goods C, al-Shaibi K, Liu M, et al.  Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting. Am J Cardiol. 1996;78:1042–1044
  45. Mehta S, Yusuf S, Peters R, et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–533

PII: S1078-5884(03)70180-4

doi: 10.1053/ejvs.2002.1794

European Journal of Vascular & Endovascular Surgery
Volume 25, Issue 1 , Pages 16-22 , January 2003

Article Tools

* Image Usage & Resolution